Zajkowska Joanna M, Izycka Aneta, Jabłońska Ewa, Hermanowska-Szpakowicz Teresa, Kondrusik Maciej, Pancewicz Sławomir, Grygorczuk Sambor, Swierzbińska Renata
Klinika Chorób Zakaźnych i Neuroinfekcji Akademii Medycznej, Białymstoku.
Pol Merkur Lekarski. 2005 Aug;19(110):152-7.
The aim was to evaluate the concentrations of the soluble forms of ICAM-1, ICAM-2, ICAM-3 in the serum and cerebrospinal fluid (CSF) of patients with neuroborreliosis and thick borne encephalitis before and after therapy in comparison with the control group.
We examined 30 patients, 10 in each group: neuroborreliosis-group I (NB), tick borne encephalitis--group II (TBE) and in the control group (group K). The diagnosis of neuroborreliosis and TBE based on the clinical features was confirmed by ELISA assays: FSME Virus/TBE Virus test (VIRION, Germany) for TBE and Borrelia IgM and IgG Recombinant (Biomedica Austria) for NB. The assays of sICAM-1, sICAM-2, sICAM-3 (ELISA, Bender Med System, USA) were performed twice in group I and II: before and after 3-4 weeks long treatment and once in control group.
Increased concentration of soluble forms of ICAM-1, ICAM-2, ICAM-3 in CSF suggest their important role in inflammatory process of viral and bacterial origin. In NB group, the serum concentrations of sICAM-1, sICAM-2 were significantly increased before and after treatment in comparison with control as well as with the analogous test results in TBE group. It may suggest NB as the part of systemic inflammation. The CSF concentration of sICAM-2 decreases after treatment in NB group in comparison with the analogous test results of TBE group. The increased CSF concentration of sICAM-2 in TBE group when compared to the CSF concentration in NB group suggest slow recovery and still persisting immunological activation in this group, even when the neurological symptoms disappeared. Increased concentrations in CSF in both diseases indicate intrameningeal activity of lymphocytes and may be a useful marker of inflammation.
旨在评估神经莱姆病和蜱传脑炎患者治疗前后血清及脑脊液(CSF)中可溶性ICAM - 1、ICAM - 2、ICAM - 3的浓度,并与对照组进行比较。
我们检查了30例患者,每组10例:神经莱姆病组I(NB)、蜱传脑炎组II(TBE)和对照组(K组)。根据临床特征诊断的神经莱姆病和蜱传脑炎通过ELISA检测得以确诊:蜱传脑炎采用FSME病毒/TBE病毒检测(德国VIRION公司),神经莱姆病采用伯氏疏螺旋体IgM和IgG重组检测(奥地利Biomedica公司)。I组和II组对可溶性ICAM - 1、ICAM - 2、ICAM - 3进行检测(ELISA法,美国Bender Med System公司):治疗前及为期3 - 4周的治疗后各检测一次,对照组检测一次。
脑脊液中可溶性ICAM - 1、ICAM - 2、ICAM - 3浓度升高表明它们在病毒和细菌源性炎症过程中起重要作用。在NB组中,与对照组以及TBE组的类似检测结果相比,治疗前后血清中sICAM - 1、sICAM - 2的浓度显著升高。这可能表明神经莱姆病是全身炎症的一部分。与TBE组的类似检测结果相比,NB组治疗后脑脊液中sICAM - 2的浓度降低。与NB组脑脊液浓度相比,TBE组脑脊液中sICAM - 2浓度升高表明该组恢复缓慢且免疫激活仍然存在,即使神经症状消失。两种疾病脑脊液中浓度升高表明淋巴细胞在脑膜内的活性,可能是炎症的一个有用标志物。